You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRCA Mutant Tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

Not yet recruiting
  • Breast Cancer
  • +7 more
  • (no location specified)
Sep 26, 2023

Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial (Biopsy, Diagnostic Imaging, Novobiocin Sodium)

Not yet recruiting
  • Metastatic Malignant Solid Neoplasm
  • Unresectable Malignant Solid Neoplasm
  • Biopsy
  • +2 more
  • (no location specified)
Jan 14, 2023

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Apr 8, 2023

Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1 Trial in Worldwide (Avelumab, Talazoparib)

Active, not recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Genes, BRCA 1
  • Palo Alto, California
  • +89 more
Jan 18, 2023

Breast Cancer Trial in Boston, Cambridge (Sapacitabine, Olaparib)

Active, not recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +1 more
May 2, 2022

NSCLC (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) Trial in San Antonio, Fairfax (RMC-9805)

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +3 more
  • San Antonio, Texas
  • +1 more
Sep 8, 2023

BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Houston (Chemotherapy, Olaparib, Therapeutic

Recruiting
  • BRCA-Mutated Ovarian Carcinoma
  • +30 more
  • Houston, Texas
    M D Anderson Cancer Center
May 27, 2022

Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,

Not yet recruiting
  • Pancreatic Acinar Cell Carcinoma
  • +6 more
  • Nab paclitaxel
  • +5 more
  • (no location specified)
Oct 30, 2023

NSCLC (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumors Trial in Irving, San Antonio,

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumors
  • Assigned interventions
  • Irving, Texas
  • +2 more
Nov 7, 2023

Advanced Solid Tumor Trial in Shanghai (SY-5933)

Recruiting
  • Advanced Solid Tumor
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 16, 2023

Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation Trial in Beijing (AB-218 capsule)

Not yet recruiting
  • Cholangiocarcinoma With IDH1 Mutation
  • Solid Tumors With IDH1 Mutation
  • AB-218 capsule
  • Beijing, Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Apr 2, 2023

Gastrointestinal Stromal Tumor of Rectum Trial in Fuzhou (Imatinib Mesylate, Local resection)

Not yet recruiting
  • Gastrointestinal Stromal Tumor of Rectum
  • Imatinib Mesylate
  • Local resection
  • Fuzhou, Fujian, China
    Weizhong Jiang
Jul 23, 2023

Tumors, Ovarian Cancer, Breast Cancer Trial in Houston (ZN-c3, Bevacizumab, Pembrolizumab)

Not yet recruiting
  • Tumors
  • +4 more
  • Houston, Texas
    MD Anderson Cancer Center
Jun 20, 2022

KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor Trial in United States (TPX-0005, Trametinib)

Active, not recruiting
  • KRAS Mutation-Related Tumors
  • +2 more
  • Los Angeles, California
  • +5 more
Nov 7, 2022

Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt

Not yet recruiting
  • Advanced Ovarian Cancer
  • None (Observational Study)
  • (no location specified)
Mar 8, 2023

KRAS G12V Mutant Advanced Epithelial Cancers Trial (Cyclophosphamide, Gemcitabine, Pembrolizumab)

Available
  • KRAS G12V Mutant Advanced Epithelial Cancers
  • (no location specified)
May 19, 2022

Primary Malignant Brain Tumor Trial in China (ABM-1310)

Not yet recruiting
  • Primary Malignant Brain Tumor
  • Beijing, Beijing, China
  • +3 more
May 28, 2023

EGFR Mutation-Related Tumors Trial (NX-019)

Not yet recruiting
  • EGFR Mutation-Related Tumors
  • (no location specified)
Aug 22, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Adavosertib)

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 28, 2022

NSCLC (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma Trial in Nashville, San Antonio, Fairfax (RMC-6291)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • +3 more
  • San Antonio, Texas
  • +1 more
Aug 16, 2022

Advanced Solid Tumor, IDH1 Mutation, Glioma Trial in Pittsburgh (ivosidenib and nivolumab)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • ivosidenib and nivolumab
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 14, 2022

NSCLC, KRAS Mutation-Related Tumors Trial in Philadelphia (Binimetinib Pill, Hydroxychloroquine Pill)

Recruiting
  • Non-Small Cell Lung Cancer
  • KRAS Mutation-Related Tumors
  • Binimetinib Pill
  • Hydroxychloroquine Pill
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Sep 30, 2022

Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • KRAS-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

Active, not recruiting
  • Advanced Breast Cancer
  • +2 more
  • Talazoparib Tosylate
  • Stanford, California
    Stanford University Hospitals and Clinics
Nov 16, 2022

EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

Recruiting
  • EGFR Exon 20 Mutation
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022